Form 4: Atara Biotherapeutics CEO Executes Tax-Related Stock Sale
Statement of Changes in Beneficial Ownership
Atara Biotherapeutics CEO AnhCo Nguyen sold 5,241 shares of common stock to satisfy tax withholding obligations related to RSU vesting.
Summary
- CEO AnhCo Nguyen sold 5,241 shares of Atara Biotherapeutics common stock on May 18, 2026.
- The sale was executed at a weighted average price of $9.1289 per share.
- The transaction was conducted automatically to cover tax withholding obligations resulting from the vesting of restricted stock units (RSUs).
- Following this transaction, the CEO retains direct ownership of 137,837 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and required for tax compliance rather than a discretionary divestment.
Positives
- The sale was non-discretionary and specifically mandated by a sale-to-cover provision in an existing equity award agreement.
- The CEO maintains a significant remaining equity stake of 137,837 shares in the company.
Negatives
- The transaction represents a reduction in the CEO's direct beneficial ownership of company stock.
Risks
- None identified; this is a routine administrative transaction related to tax compliance.
Future Outlook
No forward-looking guidance provided in this filing.
Industry Context
StockSavvy.ai notes that automatic 'sell-to-cover' transactions are standard industry practice for executives to manage tax liabilities associated with equity compensation vesting and do not typically signal a change in management sentiment regarding company performance.
Comparison to Industry Standards
- The transaction aligns with standard corporate governance practices for executive equity management.
- The use of a sale-to-cover provision is consistent with common practices among publicly traded biotechnology firms.
Stakeholder Impact
- Minimal impact on shareholders as the sale was a pre-planned tax compliance measure.
Key Dates
| Date | Description |
|---|---|
| 05/18/2026 | Date of the stock sale transaction. |
| 05/20/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Atara Biotherapeutics, ATRA, Insider Trading, Form 4, Executive Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.